June 2, 2020 | Blog
The 2019 NRDL update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas. CBPartners' blog post examines how these learnings can help shape future NRDL negotiations.
January 29, 2020 | Blog
Several factors contribute towards manufacturers seeking new ways to develop global drug pricing strategies. Product launches vary based on geography; when comparing the USA to EU, access outcomes can vary significantly based on whether or not the pivotal trial design has been optimized for each region.
November 19, 2019 | Blog
In 2011, The Cancer Drugs Fund (CDF) was launched to help patients in England access cancer drugs that had been rejected by the NHS. CBPartners' European Center of Excellence discusses the benefits of early engagement with NICE for both manufacturers and patients alike.